Clinical and preclinical systematic review of Astragalus membranaceus for viral myocarditis

Zheng, Q., Zhuang, Z., Wang, Z., Deng, L., Jin, W., Huang, Z., Zheng, G. and Wang, Y. · Oxidative Medicine and Cellular Longevity · 2020

Meta-analysis / review

View original source →

Abstract

This clinical and preclinical systematic review found that Astragalus membranaceus improved outcomes in viral myocarditis through antioxidant and immunomodulatory mechanisms, documenting a cardioprotective pharmacology of astragalus.

Referenced for these plants

How to cite

Zheng, Q., Zhuang, Z., Wang, Z., Deng, L., Jin, W., Huang, Z., Zheng, G. and Wang, Y (2020) 'Clinical and preclinical systematic review of Astragalus membranaceus for viral myocarditis', Oxidative Medicine and Cellular Longevity, 2020, pp. 1560353. doi:10.1155/2020/1560353

This reference is part of the evidence base for the Omnia Sana plant database. Source links open the original publication; Omnia Sana does not host third-party content.